Table of Contents
I spoke with David Hung, M.D. earlier in November at Jefferies 2025. Two weeks later, Nuvation Bio's stock has pumped over 70%.
Nuvation is gaining real momentum after its first FDA approval, with IBTROZI now treating a growing number of patients with ROS1-positive lung cancer.
A new Phase 3 trial is testing whether earlier use can prevent relapse. And at the same time, early success in IDH1-mutant glioma gives them a second late-stage shot on goal.
The Nuvation story is shifting from a single-asset gamble to a clearer, multi-pathway growth plan that is exciting for both clinicians and investors.
But don't take my word for it - hear it from the man himself:
I hope you enjoy watching!
Yours sincerely,
Dr. Adil Ali
